Mini-dose weekly adriamycin therapy for patients with advanced malignant disease at increased risk for adriamycin toxicity

A. Kessinger, H. M. Lemon, J. F. Foley

Research output: Contribution to journalArticle

6 Scopus citations


In an effort to administer adriamycin safely to patients with advanced progressive malignant disease and an increased risk for adriamycin toxicity, a weekly schedule of 10-20 mg of intravenous adriamycin was used for 38 patients. All patients had been previously treated with chemotherapy and/or radiation therapy. These patients also had advanced age (8), liver disease (8), previous radiation to the myocardium (18), prior bone marrow depression (21), concurrent bone marrow depression (9) and/or were intolerant to usual adriamycin dosages (2). Five patients had an objective remission and eight had disease stabilization. Toxicity was not eliminated; 39% had leukopenia (WBC<3,500); four had alopecia; nausea and vomiting forced one to stop therapy; extravasation occurred in three; vaginitis occurred in one; one had diarrhea; and one had an arrhythmia. One patient died a septic death during a leukopenic phase. Adriamycin can be given to poor-risk patients on a weekly basis using mini-doses, but severe toxicity cannot be avoided at these dosages.

Original languageEnglish (US)
Pages (from-to)113-115
Number of pages3
JournalAmerican Journal of Clinical Oncology: Cancer Clinical Trials
Issue number1
Publication statusPublished - Jan 1 1983


ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Cite this